Friday, 11 August 2017

BGB-290 (brain penentrant PARP inhibitor) trial now open in USA

Formerly this drug was only available in 2 Australian clinical trials.  A trial has now opened in the USA (Arizona, Colorado, Tennessee, not yet open in Oklahoma) for newly diagnosed GBM with unmethylated MGMT, or for recurrent GBM (methylated/unmethylated MGMT), combined with standard treatments (temozolomide + BGB-290 in the recurrent group).

https://clinicaltrials.gov/ct2/show/NCT03150862

Past post that mentioned BGB-290 and PARP inhibitors.
http://btcocktails.blogspot.com/2017/07/parp-combination-therapy.html

No comments:

Post a Comment